[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"allergic-bronchopulmonary-aspergillosis-abpa\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:allergic-bronchopulmonary-aspergillosis-abpa":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,45,70,104,129],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100638551","multi-omics-inflammatory-phenotype-for-abpa-recurrence-risk-prediction-100638551",false,"NCT07611838","Multi-Omics Inflammatory Phenotype for ABPA Recurrence Risk Prediction","Multi-Omics Data-Derived Inflammatory Phenotype for ABPA Recurrence Risk Prediction: A Multicenter Study","Inclusion Criteria:\n\n* Female and Male patients aged 18-80 years\n* diagnosis of Allergic Bronchopulmonary Aspergillosis ABPA accroding to the 2024 ISHAM Working Group Diagnostic Criteria\n\nExclusion Criteria:\n\n* Patients with malignant tumors or severe organ dysfunction (e.g., cardiac, cerebral, renal, etc.)\n* Patients with severe comorbidities, including active pulmonary tuberculosis, lung cancer, chronic heart failure (NYHA class Ⅳ), chronic kidney disease (CKD stage 5), decompensated cirrhosis, etc.\n* Patients with immunosuppressive status, such as HIV infection, long-term use of oral corticosteroids or immunosuppressive agents.\n* Pregnant or lactating women.\n* Patients with missing key data or incomplete medical records.","ALL","18 Years","80 Years",{"count":20,"type":21},300,"ESTIMATED","OBSERVATIONAL","To develop and externally validate a machine learning model for predicting the 1-year risk of relapse in patients with stable ABPA, and to further evaluate its value in risk stratification and clinical decision-making.",[25,26,27,28,29],"Allergic Bronchopulmonary Aspergillosis (ABPA)","Machine Learning","Multi-omics","Multicenter Study","Relapse",[31,29,26,28,27],"Allergic Bronchopulmonary Aspergillosis","RECRUITING","2026-05-28",{"date":35,"type":36},"2026-06-01","ACTUAL",{"date":38,"type":36},"2021-01-01",{"date":40,"type":21},"2028-12-31",{"name":42,"class":43},"Qianfoshan Hospital","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":54,"studyType":22,"phases":4,"briefSummary":55,"conditions":56,"keywords":61,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":69,"locationsCount":44},"100620828","a-cohort-study-of-the-efficacy-and-safety-of-biologics-in-patients-with-abpa-100620828","NCT07362693","A Cohort Study of the Efficacy and Safety of Biologics in Patients With ABPA","A Prospective, Multicenter, Observational Cohort Study on the Efficacy and Safety of Biological Agents in Patients With Allergic Bronchopulmonary Aspergillosis","Inclusion Criteria:\n\n1. Meet the diagnostic criteria of allergic bronchopulmonary aspergillosis, according to the ISHAM guidelines for the diagnosis and treatment of allergic bronchopulmonary aspergillosis (2024 revision).\n2. The underlying disease was bronchial asthma, and it was severe bronchial asthma.\n3. Have had an acute asthma attack in the past year. Acute exacerbation of asthma is defined as the sudden onset of wheezing, shortness of breath, cough, chest tightness and other symptoms beyond the definition of uncontrolled asthma, or the aggravation of the original symptoms, and is characterized by decreased expiratory flow, often induced by exposure to allergens, irritants or respiratory tract infection.\n4. Blood eosinophil count ≥150 cells \u002FμL.\n5. Age ≥ 18 years old.\n\nExclusion Criteria:\n\n1. The underlying diseases were chronic obstructive pulmonary disease and bronchiectasis;\n2. Known allergic history to biological agents;\n3. Human immunodeficiency virus infection, active pulmonary tuberculosis or pulmonary malignant tumor;\n4. Complicated with other diseases requiring long-term systemic use of glucocorticoids or immunosuppressants (such as autoimmune diseases);\n5. Pregnant or lactating women;\n6. Currently participating in other interventional clinical research;\n7. Any other conditions considered by the investigator to preclude participation in the study (e.g., nonadherence, predicted survival \\\u003C1 year, or severe mental illness that prevented cooperation).",{"count":53,"type":21},50,"2 Years","To evaluate the efficacy and safety of biological agents in patients with allergic bronchopulmonary aspergillosis.",[57,58,25,59,31,60],"ABPA","Biologics","Cohort Study","Efficacy and Safety",[62,31,58],"abpa","2026-04-16",{"date":65,"type":36},"2026-04-17",{"date":67,"type":36},"2025-01-31",{"date":40,"type":21},{"name":42,"class":43},{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":78,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":81,"conditions":82,"keywords":88,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":44},"100630896","immune-status-and-disease-control-of-inflammatory-airway-diseases-100630896","NCT07493629","Immune Status and Disease Control of Inflammatory Airway Diseases","Association Between Immune Status and Disease Control in Patients With Inflammatory Airway Diseases","ISDC-IAD","Inclusion Criteria\n\n1. Age ≥18 years (≥40 years for COPD patients).\n2. Clinical diagnosis of asthma, ABPA, bronchiectasis, OSAS, or COPD according to established criteria.\n3. PRISm patients (post-BD FEV1\u002FFVC ≥70% and FEV1 \\\u003C80% predicted)\n4. Smoking controls: ≥10 pack-years, normal lung function, no chronic respiratory symptoms.\n5. Healthy controls: normal lung function, FeNO \\\u003C20 ppb, total IgE \\\u003C100 IU\u002FmL, no chronic disease, smoking \\\u003C10 pack-years, no immunosuppressant use within 3 months.\n\nExclusion Criteria\n\n1. Patients with severe respiratory diseases other than those included in the study, such as pulmonary embolism, pneumothorax, pulmonary hypertension, interstitial lung disease, or active lung cancer.\n2. Patients with severe systemic diseases that may interfere with study completion, such as myocardial infarction, severe arrhythmia, hepatic insufficiency, renal insufficiency, hematological disorders, or malignancy.\n3. Patients with an acute exacerbation within 4 weeks before enrollment, or systemic use of antibiotics, antifungal drugs, immunosuppressive agents, cytotoxic agents, or corticosteroids (except for long-term maintenance therapy)\n4. Pregnant or lactating women.\n5. Patients with poor compliance as judged by the investigators.\n6. Subjects currently participating in other clinical studies.",true,{"count":80,"type":21},200,"The goal of this study is to learn how the body's immune system affects disease control in people with different airway inflammatory diseases.We want to understand:\n\n1.Whether specific immune cell patterns in the blood are linked to how severe the disease is or how well it is controlled.\n\nParticipants will:\n\n1. Answer questions about their health and symptoms.\n2. Give blood samples\n3. Have lung function tests and other standard check-ups.\n4. share sleep study results. We will compare people with airway diseases to healthy volunteers to see how their immune systems differ.",[83,84,85,86,87,25],"Airway Inflammation","Chronic Obstructive Pulmonary Disease (COPD)","Asthma (Diagnosis)","Bronchiectasis","OSAS (Obstructive Sleep Apneas Syndrome)",[89,90,91,92,93],"Airway Inflammatory Diseases","Immunophenotyping","Metabolomics","Cytometry by Time-of-Flight","High-dimensional immune profiling","2026-03-23",{"date":96,"type":36},"2026-03-25",{"date":98,"type":36},"2025-08-01",{"date":100,"type":21},"2026-08-01",{"name":102,"class":103},"First Affiliated Hospital of Ningbo University","NETWORK",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":113,"conditions":114,"keywords":119,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":128,"locationsCount":44},"100620826","a-study-of-the-efficacy-and-safety-of-bronchoscopic-airway-clearance-and-amphotericin-b-spraying-in-patients-with-abpa-100620826","NCT07362667","A Study of the Efficacy and Safety of Bronchoscopic Airway Clearance and Amphotericin B Spraying in Patients With ABPA","A Prospective, Multicenter, Observational Cohort Study on the Efficacy and Safety of Bronchoscopic Airway Clearance and Amphotericin B Spraying in Patients With Allergic Bronchopulmonary Aspergillosis","Inclusion Criteria:\n\n1. Meet the diagnostic criteria of allergic bronchopulmonary aspergillosis, according to the ISHAM guidelines for the diagnosis and treatment of allergic bronchopulmonary aspergillosis (2024 revision), and the presence of mucus plugs or hyperattenuated mucus confirmed by chest high-resolution CT (HRCT).\n2. Active disease: Newly diagnosed allergic bronchopulmonary aspergillosis or an acute exacerbation after discontinuation of treatment (defined as a \\> 14 day history of clinical worsening or radiographic progression of allergic bronchopulmonary aspergillosis and a ≥50% increase in total serum IgE from the last recorded value during the stable phase, excluding other causes of the acute exacerbation) in patients with previously diagnosed allergic bronchopulmonary aspergillosis.\n3. Age ≥ 18 years old.\n\nExclusion Criteria:\n\n1. Allergic bronchopulmonary aspergillosis - serotype (i.e., meets the diagnostic criteria for allergic bronchopulmonary aspergillosis, but chest CT shows no obvious abnormality);\n2. Patients with absolute or relative contraindications to electronic bronchoscopy;\n3. Known history of allergy to amphotericin B or any of its excipients;\n4. Patients with bronchiectasis caused by human immunodeficiency virus infection, active tuberculosis, pulmonary malignant tumor or other non-allergic bronchopulmonary aspergillosis;\n5. Combined with other diseases requiring long-term systemic use of glucocorticoids or immunosuppressants (such as autoimmune diseases);\n6. Patients with previous or current smoking history;\n7. Pregnant or lactating women;\n8. Currently participating in other interventional clinical research;\n9. Any other conditions considered by the investigator to preclude participation in the study (e.g., nonadherence, predicted survival \\\u003C1 year, or severe mental illness that prevented cooperation).",{"count":112,"type":21},44,"To evaluate the efficacy and safety of bronchoscopic airway clearance and amphotericin B spraying in the treatment of allergic bronchopulmonary aspergillosis",[57,31,25,115,116,117,118],"Airway Clearance","Mucus Plug","Amphotericin B","Bronchoscope",[31,57,117,120,115,121],"bronchoscope","mucus plug","2026-01-15",{"date":124,"type":36},"2026-01-23",{"date":126,"type":36},"2026-01-10",{"date":40,"type":21},{"name":42,"class":43},{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":78,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":44},"100596044","pathogenesis-and-inflammatory-phenotype-of-allergic-bronchopulmonary-aspergillosis-100596044","NCT07040332","Pathogenesis and Inflammatory Phenotype of Allergic Bronchopulmonary Aspergillosis","Inclusion Criteria:\n\n* Meets the diagnostic criteria for allergic bronchopulmonary aspergillosis.\n* Meets the diagnostic criteria for fungal-sensitized asthma.\n\nExclusion Criteria:\n\n* Human immunodeficiency virus infection.\n* Malignant tumor.\n* Blood system disease.\n* autoimmune system disease.\n* History of pulmonary tuberculosis.\n* Patients with a history of smoking or still smoking.\n* Invasive pulmonary fungal disease.\n* Contraindications electronic bronchoscopy",{"count":136,"type":21},140,"This study aims to reveal the immune and inflammatory regulatory molecular mechanisms related to the progression of allergic bronchopulmonary aspergillosis (ABPA), and to build a precision typing based on inflammation and identify the biomarkers of typing, and to explore the clinical outcomes of different inflammatory phenotypes.",[25],"2025-07-01",{"date":141,"type":36},"2025-07-04",{"date":143,"type":36},"2025-05-10",{"date":145,"type":21},"2029-01-31",{"name":42,"class":43}]